Latest News

German vaccine maker CureVac surges almost 250% in Nasdaq debut



Shares of German biotech company CureVac, which is developing a leading coronavirus vaccine candidate, rocketed Friday in its first day of trading in New York after raising more than $200 million in an initial public offering.

Source link

Related posts

Genetic testing in women diagnosed with breast cancer decreases cost of care nationwide

Newsemia

Removing copper from blood can destroy deadliest cancers that are resistant to immunotherapy

Newsemia

STAT Plus: Up and down the ladder: The latest comings and goings

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World